tofacitinib · Xeljanz

Small molecule

Also known as CP-690550

Approvedregulatory verdict

Evidence outlook

Approved: Psoriatic Arthritis, Ulcerative Colitis, Rheumatoid Arthritis

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (6)
US
  • Active ankylosing spondylitis (AS), who have had an inadequate response or intolerance to one or more TNF blockers
  • Active polyarticular course juvenile idiopathic arthritis (pcJIA), who have had an inadequate response or intolerance to one or more TNF blockers
Product first approved 2012Outside this platform's coveragedailymed.nlm.nih.gov
UK
  • Moderately to severely active ulcerative colitis in adult patients
Product first approved 2018medicines.org.uk
EU
  • Rheumatoid arthritisTofacitinib in combination with methotrexate (MTX) is indicated for the treatment of moderate to severe active rheumatoid arthritis (RA) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (DMARDs) (see section 5.1). Tofacitinib can be given as monotherapy in case of intolerance to MTX or when treatment with MTX is inappropriate (see sections 4.4 and 4.5). Psoriatic arthritisTofacitinib in combination with MTX is indicated for the treatment of active psoriatic arthritis (PsA) in adult patients...
Product first approved 2017EMA
CA
  • Rheumatoid Arthritis XELJANZ/XELJANZ XR (tofacitinib), in combination with methotrexate (MTX), is indicated for reducing the signs and symptoms of rheumatoid arthritis (RA) in adult patients with moderately to severely active RA who have had an inadequate response to MTX and to one or more disease-modifying anti-rheumatic drugs (DMARDs). In cases of intolerance to MTX and other DMARDs, physicians may consider the use of XELJANZ/XELJANZ XR (tofacitinib) as monotherapy. Psoriatic Arthritis XELJANZ (tofacitinib), in combination with methotrexate (MTX) or another conventional synthetic...
Product first approved 2014Health Canada
JP
  • Treatment of rheumatoid arthritis in patients who have not sufficiently responded to conventional treatments
Product first approved 2013PMDA

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (40)
Psoriatic Arthritis
NCT04610476 · University of Erlangen-Nürnberg Medical School
2020-10-19 – 2025-10-19 · Psoriatic Arthritis, Withdrawal, Reduction
What this study did
NCT03486457 · Pfizer
2018-08-10 – 2021-04-28 · Psoriatic Arthritis
What this study did
NCT03736161 · Globe Pharmaceuticals Limited
2017-09-15 – 2019-09-28 · Psoriatic Arthritis
What this study did
NCT01976364 · Pfizer
2014-02-17 – 2019-05-20 · Arthritis, Psoriatic
What this study did
Rheumatoid Arthritis
NCT03414502 · University of Nebraska
2007-12-10 – 2029-03 · Rheumatoid Arthritis
What this study did
NCT07008846 · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
2025-05-10 – 2026-09-30 · Moderate to Severe Rheumatoid Arthritis
What this study did
NCT00413699 · Pfizer
2007-02-05 – 2017-10-26 · Arthritis, Rheumatoid
What this study did
NCT00661661 · Pfizer
2008-04 – 2013-12 · Rheumatoid Arthritis
What this study did
Ulcerative Colitis
NCT04624230 · Pfizer
2021-08-12 – 2029-06-06 · Ulcerative Colitis
What this study did
Other / comorbidity
NCT06654882 · Duke University
2026-01-09 – 2029-11 · Polyarticular Course Juvenile Idiopathic Arthritis (JIA)
What this study did
NCT04871191 · Assistance Publique - Hôpitaux de Paris
2025-06-06 – 2029-03 · Granulomatosis With Polyangiitis, Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
What this study did
NCT06172361 · Zhejiang University
2024-01-20 – 2026-05-30 · Polymyalgia Rheumatica
What this study did
NCT05326464 · University of Texas Southwestern Medical Center
2022-10-07 – 2025-10-31 · Glioblastoma
What this study did
NCT05749666 · Chinese SLE Treatment And Research Group
2023-01-20 – 2025-07-20 · Takayasu Arteritis
What this study did
NCT03000439 · Pfizer
2018-05-10 – 2024-03-27 · Arthritis Juvenile Idiopathic
What this study did
NCT06278402 · Jinnah Hospital
2023-07-01 – 2024-01-16 · Alopecia Areata, Alopecia Totalis, Alopecia Universalis
What this study did
NCT04469114 · Hospital Israelita Albert Einstein
2020-09-16 – 2021-01-09 · Covid19
What this study did
NCT03502616 · Pfizer
2018-06-07 – 2020-08-20 · Ankylosing Spondylitis
What this study did
NCT02592434 · Pfizer
2016-06-10 – 2019-05-16 · Juvenile Idiopathic Arthritis
What this study did
NCT01815424 · Pfizer
2013-12 – 2015-07 · Psoriasis
What this study did
Phase 2/3 (3)
Other / comorbidity
NCT06011343 · Hospital Universitário Professor Edgard Santos
2023-10-01 – 2025-07-01 · Cutaneous Leishmaniasis, American
What this study did
NCT01500551 · Pfizer
2013-03-18 – 2025-02-12 · Juvenile Idiopathic Arthritis
What this study did
NCT03738956 · Globe Pharmaceuticals Limited
2017-09-01 – 2018-12-31 · Axial Spondyloarthritis
What this study did
Phase 2 (57)
Psoriatic Arthritis
NCT04062695 · Charite University, Berlin, Germany
2020-08-04 – 2023-12 · Psoriatic Arthritis, Spondylitis, Sacroilitis
What this study did
Rheumatoid Arthritis
NCT03755466 · Shinshu University
2018-11-21 – 2025-11-20 · Rheumatoid Arthritis
What this study did
NCT05246293 · National Institute of Respiratory Diseases, Mexico
2022-08-08 – 2025-03-02 · Rheumatoid Arthritis, Interstitial Lung Disease
What this study did
NCT00976599 · Pfizer
2009-11 – 2011-07 · Rheumatoid Arthritis
What this study did
NCT01059864 · Pfizer
2010-02 – 2010-11 · Rheumatoid Arthritis
What this study did
NCT00687193 · Pfizer
2009-03 – 2010-07 · Arthritis, Rheumatoid
What this study did
NCT00550446 · Pfizer
2007-09 – 2009-01 · Arthritis, Rheumatoid
What this study did
NCT00603512 · Pfizer
2008-01 – 2008-09 · Arthritis, Rheumatoid
What this study did
NCT00413660 · Pfizer
2007-01 – 2008-08 · Arthritis, Rheumatoid
What this study did
NCT00147498 · Pfizer
2005-01 – 2006-06 · Rheumatoid Arthritis
What this study did
Ulcerative Colitis
NCT04925973 · McMaster University
2021-06-01 – 2023-12 · Ulcerative Colitis Acute
What this study did
NCT00787202 · Pfizer
2008-12 – 2010-09 · Ulcerative Colitis
What this study did
Other / comorbidity
NCT07281456 · National Institute of Dental and Craniofacial Research (NIDCR)
2025-12-18 – 2030-12-15 · Sjogren's Syndrome
What this study did
NCT07598643 · University of Colorado, Denver
2026-05-28 – 2030-08 · Down Syndrome
What this study did
NCT07522801 · Philippe ROUSSELOT
2026-09-01 – 2030-03-01 · LAL
What this study did
NCT07925866 · Anhui Provincial Hospital
2025-07-10 – 2028-06-30 · Patients With Locally Advanced or Metastatic NSCLC Who Have Failed First-line Immunotherapy
What this study did
NCT07138898 · NYU Langone Health
2025-12-12 – 2028-01 · Rheumatic Disease
What this study did
NCT07547930 · The First Affiliated Hospital of Xiamen University
2026-04-24 – 2027-12-30 · Thyroid Eye Disease, TED, Graves Ophthalmopathy, Graves Orbitopathy
What this study did
NCT07313072 · Hexsel Dermatology Clinic
2026-09-01 – 2027-09 · Nail Psoriasis
What this study did
NCT03681275 · Stanford University
2019-09-03 – 2027-08-31 · Diaphragm Injury
What this study did
NCT05845723 · Peking Union Medical College Hospital
2023-06-01 – 2027-06-01 · Aneurysm, Behcet Syndrome, Vascular Type
What this study did
NCT05662228 · University of Colorado, Denver
2023-06-29 – 2026-05-28 · Down Syndrome, Regression
What this study did
NCT06393972 · Shanghai Zhongshan Hospital
2024-04-10 – 2025-12-16 · Glucocorticoid Resistant ICIs-related Myocarditis
What this study did
NCT06810050 · CAGE Bio Inc.
2024-12-18 – 2025-10-30 · Atopic Dermatitis (AD)
What this study did
NCT05348213 · Ruijin Hospital
2022-05-16 – 2025-06-01 · Diffuse Large B Cell Lymphoma
What this study did
NCT04246372 · University of Colorado, Denver
2020-10-21 – 2024-10-30 · Down Syndrome, Alopecia Areata, Atopic Dermatitis / Eczema, Hidradenitis Suppurativa, Vitiligo, Psoriasis
What this study did
NCT06044844 · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
2023-11 – 2024-05 · Efficacy of Tofacitinib in the Systemic Sclerosis
What this study did
NCT04768504 · Khashayar Esfahani
2022-03-22 – 2024-01-17 · Immune-Mediated Colitis
What this study did
NCT05087589 · Peking University People's Hospital
2021-11-20 – 2023-10-01 · Primary Sjögren's Syndrome
What this study did
NCT05400889 · Peking University People's Hospital
2022-06-10 – 2023-06-01 · Idiopathic Inflammatory Myopathies
What this study did
NCT04580277 · Cedars-Sinai Medical Center
2021-01-25 – 2023-05-15 · Pouchitis, Ileal Pouchitis, Ileal Pouch
What this study did
NCT04799262 · RenJi Hospital
2021-01-01 – 2022-05-01 · Polymyalgia Rheumatica, Effect of Drug, Safety Issues
What this study did
NCT03598959 · Sichuan University
2019-01-01 – 2021-12-31 · Extranodal NK/T-cell Lymphoma
What this study did
NCT03580343 · Washington University School of Medicine
2019-04-04 – 2021-04-04 · Uveitis, Scleritis
What this study did
NCT04415151 · Yale University
2020-10-14 – 2021-02-28 · COVID-19 Pneumonia
What this study did
NCT04390061 · Università Politecnica delle Marche
2020-06 – 2020-10 · Pneumonitis, Interstitial, COVID-19
What this study did
NCT04750317 · I.M. Sechenov First Moscow State Medical University
2020-05-11 – 2020-09-01 · COVID-19
What this study did
NCT04332042 · Università Politecnica delle Marche
2020-04-10 – 2020-07-10 · SARS-COv2 Related Interstitial Pneumonia
What this study did
NCT02299297 · Columbia University
2015-01 – 2017-12 · Alopecia Areata
What this study did
NCT01470599 · Pfizer
2012-04 – 2016-07 · Crohn's Disease
What this study did
NCT01393899 · Pfizer
2012-03 – 2015-07 · Crohn's Disease
What this study did
NCT02197455 · Yale University
2014-07 – 2015-07 · Alopecia Areata (AA), Alopecia Totalis (AT), Alopecia Universalis (AU)
What this study did
NCT00658359 · Pfizer
2008-08 – 2015-06 · Kidney Transplantation
What this study did
NCT01786668 · Pfizer
2013-04 – 2015-03 · Ankylosing Spondylitis
What this study did
NCT01393626 · Pfizer
2011-10 – 2015-03 · Crohn's Disease
What this study did
NCT00263328 · Pfizer
2005-12 – 2014-06 · Kidney Transplantation
What this study did
Phase 1/2 (7)
Other / comorbidity
NCT05104723 · National Institute of Allergy and Infectious Diseases (NIAID)
2022-08-12 – 2026-05-04 · Chronic Granulomatous Disease, Inflammatory Gastrointestinal Disease, Inflammatory Skin Disease, Inflammatory Lung Disease
What this study did
NCT04496960 · National Institute of Dental and Craniofacial Research (NIDCR)
2021-05-18 – 2025-01-14 · Sjogren's Syndrome
What this study did
NCT03288324 · Children's Hospital Medical Center, Cincinnati
2017-08-23 – 2023-12-01 · Cutaneous Lupus, Systemic Lupus Erythematosus
What this study did
NCT05487963 · CAGE Bio Inc.
2022-11-09 – 2023-07-30 · Atopic Dermatitis
What this study did
NCT04141904 · University of Oxford
2020-02-10 – 2022-05-23 · Depression, Inflammation
What this study did
NCT03274076 · University of Michigan
2017-09-25 – 2019-11-15 · Systemic Sclerosis, Scleroderma
What this study did
NCT00784719 · Pfizer
2008-11 – 2009-10 · Dry Eye Syndromes
What this study did
Phase 1 (53)
Rheumatoid Arthritis
NCT03868072 · Chong Kun Dang Pharmaceutical
2019-02-22 – 2019-04-20 · Rheumatoid Arthritis
What this study did
NCT01741493 · AbbVie (prior sponsor, Abbott)
2012-11 – 2013-12 · Rheumatoid Arthritis
What this study did
NCT01484561 · Pfizer
2012-04 – 2013-02 · Arthritis, Rheumatoid
What this study did
NCT01405118 · Pfizer
2011-06 – 2011-07 · Rheumatoid Arthritis
What this study did
NCT01023100 · Pfizer
2010-03 – 2010-03 · Arthritis, Rheumatoid
What this study did
NCT01745055 · Pfizer
2005-04 – 2006-06 · Rheumatoid Arthritis
What this study did
Ulcerative Colitis
NCT03103412 · Theravance Biopharma
2017-05-04 – 2017-11-08 · Active Mild Ulcerative Colitis, Active Moderate Ulcerative Colitis, Healthy Subjects
What this study did
Other / comorbidity
NCT07055529 · Hayat Abad Medical Complex, Peshawar
2026-06-01 – 2026-12-31 · Vitiligo, Generalized
What this study did
NCT07843693 · AbbVie
2026-08-26 – 2026-12 · Healthy Volunteers
What this study did
NCT06689982 · Beijing Tiantan Hospital
2024-12-01 – 2026-06-01 · Amyotrophic Lateral Sclerosis
What this study did
NCT07261306 · Lahore General Hospital
2025-08-29 – 2025-12-25 · Psoriasis
What this study did
NCT06119490 · Peng Zhang
2023-07-05 – 2025-11-09 · Toxic Epidermal Necrolysis
What this study did
NCT07044141 · Lahore General Hospital
2025-03-01 – 2025-09-30 · Vitiligo
What this study did
NCT04431895 · Huashan Hospital
2020-06-11 – 2024-03-31 · Myasthenia Gravis, Generalized
What this study did
NCT05048238 · National Institute of Allergy and Infectious Diseases (NIAID)
2022-09-30 – 2024-02-29 · Cutaneous Lupus
What this study did
NCT05293119 · Pi Research Consultancy Center, Bangladesh
2022-05-30 – 2023-11-30 · Vitiligo, Effect of Drug
What this study did
NCT06157905 · Services Institute of Medical Sciences, Pakistan
2022-08-06 – 2023-08-04 · Extensive Alopecia Areata
What this study did
NCT04034238 · National Cancer Institute (NCI)
2019-08-29 – 2021-11-19 · Neoplasms With Mesothelin Expression, Epithelioid Mesothelioma, Cholangiocarcinoma, Extrahepatic, Adenocarcinoma, Pancreatic
What this study did
NCT04985955 · Janssen Research & Development, LLC
2021-07-30 – 2021-09-21 · Healthy
What this study did
NCT03793439 · Oregon Health and Science University
2019-05-15 – 2021-06-24 · Sarcoidosis, Pulmonary, Sarcoidosis Lung, Sarcoidosis
What this study did
NCT03910543 · Yale University
2019-04-11 – 2021-06-01 · Cutaneous Sarcoidosis, Granuloma Annulare
What this study did
NCT04468425 · TWi Biotechnology, Inc.
2020-10-14 – 2020-12-21 · Healthy Subjects
What this study did
NCT03002649 · Johns Hopkins University
2017-01 – 2020-09-30 · Dermatomyositis
What this study did
NCT03159936 · Tufts Medical Center
2017-04-03 – 2020-06-10 · Discoid Lupus Erythematosus, Systemic Lupus Erythematosus
What this study did
NCT04111614 · Pfizer
2019-10-11 – 2019-12-12 · Healthy
What this study did
NCT04403776 · Pfizer
2018-12-03 – 2019-02-12 · Healthy
What this study did
NCT02535689 · National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
2015-08-28 – 2018-04-26 · Systemic Lupus Erythematosus
What this study did
NCT03112148 · Pfizer
2017-09-11 – 2017-11-15 · Healthy
What this study did
NCT01513902 · Pfizer
2013-03 – 2015-12 · Juvenile Idiopathic Arthritis
What this study did
NCT01599377 · Pfizer
2012-05 – 2012-07 · Healthy
What this study did
NCT01204112 · Pfizer
2010-09 – 2010-10 · Healthy
What this study did
NCT01101919 · Pfizer
2010-10 – 2010-10 · Healthy
What this study did
NCT01202240 · Pfizer
2010-09 – 2010-09 · Healthy
What this study did
NCT01137708 · Pfizer
2010-06 – 2010-07 · Healthy
What this study did
NCT00969813 · Pfizer
2009-11 – 2010-01 · Hepatic Insufficiency
What this study did
NCT00860496 · Pfizer
2009-06 – 2009-08 · Healthy Volunteers
What this study did
NCT00902460 · Pfizer
2009-06 – 2009-07 · Healthy Volunteer
What this study did
NCT01743677 · Pfizer
2007-10-26 – 2008-02-09 · Healthy
What this study did
NCT01710033 · Pfizer
2003-09 – 2005-04 · Kidney Transplant
What this study did
Phase 4 (38)
Rheumatoid Arthritis
NCT06687551 · University Hospital, Toulouse
2025-06-06 – 2029-04-01 · Rheumatoid Arthritis (RA
What this study did
NCT06945666 · Jie Chang
2025-08-01 – 2027-05-31 · Rheumatoid Arthritis (RA
What this study did
NCT07636057 · Sheikh Zayed Federal Postgraduate Medical Institute
2026-07-05 – 2027-05-10 · Rheumatoid Arthritis (RA)
What this study did
NCT07554820 · Shaikh Zayed Hospital, Lahore
2025-12-06 – 2026-09-30 · Rheumatoid Arthritis, Major Adverse Cardiac Events
What this study did
NCT03976245 · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
2020-03-01 – 2025-03 · Rheumatoid Arthritis
What this study did
NCT05606107 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2022-05-20 – 2024-12-31 · Rheumatoid Arthritis
What this study did
NCT05080218 · Jeffrey Curtis
2021-11-15 – 2024-05-28 · Rheumatoid Arthritis, Psoriatic Arthritis, Spondylarthritis
What this study did
NCT04311567 · Vastra Gotaland Region
2020-11-07 – 2024-03-26 · Rheumatoid Arthritis, Interstitial Lung Disease Due to Systemic Disease (Disorder), RA, ILD
What this study did
NCT04927000 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2021-05-31 – 2023-12-30 · Rheumatoid Arthritis
What this study did
NCT04928066 · Qilu Hospital of Shandong University
2020-03-01 – 2023-07-30 · Arthritis, Rheumatoid
What this study did
NCT04464642 · Dr. Mohammad Mamun Khan
2019-07-10 – 2020-09 · Rheumatoid Arthritis
What this study did
NCT02831855 · Pfizer
2016-09-01 – 2018-12-17 · Rheumatoid Arthritis
What this study did
NCT02321930 · University of California, Los Angeles
2016-02-16 – 2017-09-29 · Rheumatoid Arthritis
What this study did
Ulcerative Colitis
NCT06095128 · Takeda
2024-06-12 – 2027-07-09 · Ulcerative Colitis
What this study did
NCT05313620 · Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
2022-04-01 – 2026-06-11 · Ulcerative Colitis, Thromboembolism
What this study did
NCT06625450 · Post Graduate Institute of Medical Education and Research, Chandigarh
2024-10 – 2026-01 · Ulcerative Colitis
What this study did
NCT04743518 · Centre Hospitalier Universitaire, Amiens
2021-02-02 – 2025-12 · Ulcerative Colitis
What this study did
NCT03885713 · Fundación de Investigación Biomédica - Hospital Universitario de La Princesa
2019-09-10 – 2024-12-31 · Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis
What this study did
NCT03281304 · Pfizer
2017-11-16 – 2022-03-18 · Ulcerative Colitis
What this study did
Other / comorbidity
NCT07352566 · University of California, San Francisco
2026-08-01 – 2030-06-01 · Psoriasis, Atopic Dermatitis
What this study did
NCT06660329 · Peking Union Medical College Hospital
2024-10-01 – 2028-10-01 · Blau Syndrome
What this study did
NCT07131813 · All India Institute of Medical Sciences, Bhubaneswar
2025-10-10 – 2027-06-01 · Oral Lichen Planus
What this study did
NCT06438679 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2024-03-19 – 2026-12 · Dermatomyositis
What this study did
NCT07406204 · Hayat Abad Medical Complex, Peshawar
2026-02-15 – 2026-08-15 · Alopecia Areata, Alopecia Totalis (AT), Alopecia Universalis
What this study did
NCT06465732 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2025-01 – 2026-07 · Atopic Dermatitis
What this study did
NCT06112665 · Charite University, Berlin, Germany
2023-11-10 – 2026-06 · Axial Spondyloarthritis
What this study did
NCT05102448 · Shanghai Zhongshan Hospital
2021-11-01 – 2025-12-31 · Takayasu Arteritis
What this study did
NCT06998875 · Army Medical University, China
2025-03-01 – 2025-12 · Primary Cutaneous Amyloidosis
What this study did
NCT07472166 · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
2024-12-21 – 2025-08-30 · Scleroderma, Systemic
What this study did
NCT04944524 · Shanghai Zhongshan Hospital
2021-07-01 – 2024-07-01 · Granulomatosis With Polyangiitis
What this study did
NCT04485325 · Dr. Frank Behrens
2019-11-04 – 2024-03-31 · Rheumatic Arthritis
What this study did
NCT06310057 · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
2022-01-01 – 2024-03-01 · Axial Spondyloarthritis
What this study did
NCT04299971 · Shanghai Zhongshan Hospital
2020-03-01 – 2023-12-31 · Takayasu Arteritis, Methotrexate, Inhibition, Treatment
What this study did
NCT03800979 · Institute of Dermatology, Thailand
2019-01-12 – 2021-01-30 · Alopecia Areata
What this study did
NCT03504072 · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
2018-01-16 – 2019-12-31 · Spondyloarthritis
What this study did
NCT02187055 · Pfizer
2014-08 – 2016-12 · Rhematoid Arthritis
What this study did
Early phase / not applicable (11)
Rheumatoid Arthritis
NCT03815578 · University Hospital, Bordeaux
2019-06-17 – 2023-04-28 · Rheumatoid Arthritis
What this study did
Ulcerative Colitis
NCT05112263 · Post Graduate Institute of Medical Education and Research, Chandigarh
2023-07-01 – 2026-06-01 · Ulcerative Colitis
What this study did
Other / comorbidity
NCT06707246 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2024-12-15 – 2027-10 · Hidradenitis Suppurativa
What this study did
NCT07343635 · The Fourth Affiliated Hospital of Zhejiang University School of Medicine
2026-02-01 – 2027-07-01 · Erythematotelangiectatic Rosacea
What this study did
NCT07581418 · Pak Emirates Military Hospital
2026-06-01 – 2026-12-01 · Chronic Plaque Psoriasis
What this study did
NCT07827469 · Peking University People's Hospital
2023-04-01 – 2026-06-03 · Immunoglobulin G4-Related Disease, Janus Kinase Inhibitors
What this study did
NCT06201715 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2024-05-01 – 2025-12-30 · Prurigo Nodularis, Itch
What this study did
NCT06474078 · Chang Gung Memorial Hospital
2022-08-01 – 2025-06-20 · Stevens-Johnson Syndrome, Toxic Epidermal Necrolysis
What this study did
NCT06202560 · Institute of Dermatology, Thailand
2023-11-29 – 2024-07-10 · Frontal Fibrosing Alopecia, Lichen Planopilaris of Scalp
What this study did
NCT04973033 · Shanghai Zhongshan Hospital
2019-12-01 – 2021-01-31 · ANCA Associated Vasculitis, Drug Use, JAK-STAT Pathway Deregulation
What this study did
NCT02312882 · Stanford University
2014-12 – 2015-08 · Alopecia Areata, Alopecia Totalis, Alopecia Universalis
What this study did
Used as active comparator (15)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (4)
Rheumatoid Arthritis
NCT06020144 · Hangzhou Highlightll Pharmaceutical Co., Ltd
2023-11-15 – 2026-08-20 · Rheumatoid Arthritis
What this study did
Other / comorbidity
NCT07530367 · Second Affiliated Hospital, Zhejiang University, School of Medicine
2026-08-01 – 2030-12-30 · Palmoplantar Pustulosis (PPP)
What this study did
Phase 2 (8)
Psoriatic Arthritis
NCT07406035 · Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
2026-07-16 – 2027-11 · Psoriatic Arthritis
What this study did
NCT06176508 · Hansoh BioMedical R&D Company
2024-02-26 – 2026-08-28 · Psoriatic Arthritis
What this study did
Rheumatoid Arthritis
NCT05133297 · Hangzhou Highlightll Pharmaceutical Co., Ltd
2022-02-16 – 2023-05-30 · Rheumatoid Arthritis
What this study did
NCT02996500 · Pfizer
2016-11-10 – 2018-08-15 · Rheumatoid Arthritis
What this study did
Ulcerative Colitis
NCT07297069 · Asian Institute of Gastroenterology, India
2026-01-01 – 2027-12-31 · Acute Severe Ulcerative Colitis
What this study did
Other / comorbidity
NCT06114407 · Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
2023-10-30 – 2024-12-30 · Spondyloarthritis, Axial
What this study did
NCT05814939 · Jiangsu vcare pharmaceutical technology co., LTD
2023-04-26 – 2024-05-11 · Active Ankylosing Spondylitis
What this study did
Phase 1 (2)
Other / comorbidity
NCT04552197 · Janssen Research & Development, LLC
2020-09-02 – 2020-12-29 · Healthy
What this study did
NCT04114461 · Hanlim Pharm. Co., Ltd.
2019-11-06 – 2019-12-04 · Healthy Volunteers
What this study did
Phase 4 (1)
Other / comorbidity
NCT05151848 · Chinese SLE Treatment And Research Group
2022-01-05 – 2026-01-15 · Takayasu Arteritis
What this study did
Appears in other studies (7)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 2 (6)
Other / comorbidity
NCT06698822 · M.D. Anderson Cancer Center
2025-03-10 – 2027-10-19 · Cutaneous T-Cell Lymphoma
What this study did
NCT06923228 · CAGE Bio Inc.
2025-04-21 – 2025-09-30 · Atopic Dermatitis (AD)
What this study did
NCT02812342 · Yale University
2016-09 – 2018-12 · Alopecia Areata, Alopecia Totalis, Alopecia Universalis
What this study did
NCT02001181 · Pfizer
2013-12 – 2014-09 · Dermatitis, Atopic
What this study did
NCT01831466 · Pfizer
2013-05 – 2014-09 · Psoriasis Vulgaris, Psoriasis
What this study did
NCT01246583 · Pfizer
2011-02-16 – 2011-11-29 · Psoriasis
What this study did
Phase 1 (1)
Other / comorbidity
NCT02193815 · Pfizer
2014-09 – 2015-02 · Psoriasis Vulgaris
What this study did

Competitive landscape

7 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Rheumatoid Arthritis: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Tofacitinib (Xeljanz): this drugApprovedSmall moleculeJAK, JAK1/JAK3Weak signalFeatured results are non-efficacy only in this race
Abatacept (Orencia)ApprovedProtein / enzyme therapeuticCD80/CD86 (CTLA-4-Ig), Selective T Cell Costimulation Modulator, CD80/CD86 (B7-1/B7-2) on antigen-presenting cellsReliable signal
NCT00048568: Number of American College of Rheumatology 20 (ACR 20) Responders at Day 169 (Day 169): ABA + MTX DB 288/424 (67.9%) vs MTX + Placebo DB 85/214 (39.7%)
NCT00048581: Double-blind Period (DB); Number of Participants With American College of Rheumatology (ACR) 20 Response at Day 169 (Day 169): Abatacept (ABA) 129/256 (50.4%) vs Placebo (PLA) 26/133 (19.5%)
Adalimumab (Humira)ApprovedMonoclonal antibodyTNF-alphaReliable signal
NCT00195702: Primary 1, ACR20 at week 24: 63% (40 mg every other week) and 61% (20 mg weekly) vs 30% placebo, all with methotrexate (P<=0.001 for each), met. Primary 2, change in modified total Sharp score at week 52: 0.1 and 0.8 vs 2.7 (P<=0.001 for each), met. Primary 3, change in HAQ disability index at week 52: -0.59 and -0.61 vs -0.25 (P<=0.001 for each), met.
Adalimumab-Aacf (Idacio)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Aaty (Yuflyma)ApprovedMonoclonal antibodyTNF-alphaPartial signal
NCT03789292: ACR20 response at week 24, CT-P17 vs EU-adalimumab (ITT): 82.7% (268/324) in both groups; treatment difference 95% CI -5.94 to 5.94 (margin -15 to 15%) and 90% CI -4.98 to 4.98 (margin -12 to 15%), both within the predefined equivalence margins (Kay 2021, Arthritis Res Ther).
Adalimumab-Adaz (Hyrimoz)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Adbm (Cyltezo)ApprovedMonoclonal antibodyTNF-alphaReliable signalNo reviewed efficacy summary in this indication
Adalimumab-Afzb (Abrilada)ApprovedMonoclonal antibodyTNF-alphaReliable signal
NCT02480153: Percentage of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 12: Period 1 (Week 12): Period 1: PF-06410293 68.35% vs Period 1: Adalimumab-EU 71.33%
Adalimumab-Aqvh (Yusimry)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Atto (Amjevita)ApprovedMonoclonal antibodyTNF-alphaReliable signalFeatured results are non-efficacy only in this race
Adalimumab-Bwwd (Hadlima)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Fkjp (Hulio)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Adalimumab-Ryvk (Simlandi)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
AnakinraApprovedProtein / enzyme therapeuticInterleukin-1 Receptor AntagonistWeak signalNo reviewed efficacy summary in this indication
Baricitinib (Olumiant)ApprovedSmall moleculeJAK, JAK1/2Reliable signal
NCT02265705: ACR20 response at Week 12 (primary endpoint, 290 randomized, 145 per arm): 58.6% baricitinib 4mg vs 28.3% placebo (OR 4.1, 95% CI 2.5-6.9; p=0.001)
NCT01710358: ACR20 response at Week 12 (primary endpoint): 70% baricitinib 4mg vs 40% placebo (P<0.001)
BAT1806 (Tofidence)ApprovedMonoclonal antibodyIL-6 receptorPartial signal
NCT03830203: ACR20 response rate at week 24: 67.9% reference tocilizumab vs 69.9% BAT1806/BIIB800; treatment difference 1.9% (90% CI -4.0 to 7.9), within predefined equivalence margins
Certolizumab Pegol (Cimzia)ApprovedAntibody fragmentTNF-alphaWeak signalFeatured results are non-efficacy only in this race
CT-P47 (tocilizumab) (Avtozma)ApprovedMonoclonal antibodyIL-6R antagonistReliable signal
NCT05489224: Mean Change From Baseline in Disease Activity Score 28 (DAS28) Using Erythrocyte Sedimentation Rate (ESR) at Week 24 (Week 24): CT-P47 -3.77 units on a scale (Standard Error 0.12) vs RoActemra -3.67 units on a scale (Standard Error 0.118)
NCT05725434: 12-week, single-arm, open-label Phase 3 usability study: Post-Self-Injection Assessment Questionnaire (POST-SIAQ) domain scores at Week 2 exceeded 8/10 for all domains except self-confidence (7.11) and satisfaction with self-injection (7.98); the study is reported to have met its primary usability endpoint, with no autoinjector malfunctions and no new safety signals.
Etanercept (Enbrel)ApprovedProtein / enzyme therapeuticTNF-alpha, TNF-alpha / TNF-beta (lymphotoxin-alpha)Partial signal
NCT03780959: Percentage of Participants With Disease Flare in Part 2 (End of part 1 (day 90) and months 4 to 7): Part 2: Etanercept 0.4 mg/kg 28% vs Part 2: Placebo 81%
Golimumab (Simponi)ApprovedMonoclonal antibodyTNF-alphaPartial signal
NCT00264550: Co-primary 1, ACR20 response at week 14 vs placebo plus methotrexate (44/133, 33.1%): combined golimumab plus methotrexate 99/178 (55.6%), p<0.001, the prespecified primary test, met; golimumab 50 mg plus methotrexate 49/89 (55.1%), p=0.001; golimumab 100 mg plus methotrexate 50/89 (56.2%), p<0.001. Co-primary 2, median HAQ improvement at week 24 vs placebo plus methotrexate (0.125): combined golimumab plus methotrexate 0.4375, p<0.001, met; 50 mg plus methotrexate 0.375, p<0.001; 100 mg plus methotrexate 0.500, p<0.001. Golimumab 100 mg alone vs placebo plus methotrexate (for ACR20, tested only after a positive primary test): ACR20 59/133 (44.4%), p=0.059; HAQ 0.125, p=0.240; not significant.
NCT00264537: ACR50 response at Week 24: placebo+MTX 47/160 vs combined golimumab+MTX (50mg or 100mg)+MTX 122/318; CMH p=0.053. Individually: golimumab 50mg+MTX 64/159 vs placebo+MTX 47/160, p=0.042; golimumab 100mg+MTX 58/159 vs placebo+MTX, p=0.177.
HydroxychloroquineApprovedSmall moleculeAutophagy/lysosomal acidificationnot yet gradedNo reviewed efficacy summary in this indication
Infliximab (Remicade)ApprovedMonoclonal antibodyTNF-alphaReliable signalNo reviewed efficacy summary in this indication
Infliximab-Abda (Renflexis)ApprovedMonoclonal antibodyTNF-alphanot yet gradedNo reviewed efficacy summary in this indication
Infliximab-Axxq (Avsola)ApprovedMonoclonal antibodyTNF-alphaPartial signalFeatured results are non-efficacy only in this race
Infliximab-Dyyb (Inflectra)ApprovedMonoclonal antibodyTNF-alphaReliable signalFeatured results are pharmacokinetic only in this race
Infliximab-Qbtx (Ixifi)ApprovedMonoclonal antibodyTNF-alphaReliable signal
NCT02222493: Number of Participants With an American College of Rheumatology 20% (ACR20) Response at Week 14: Period 1 (Week 14): Period 1: PF-06438179 198/324 (61.1%) vs Period 1: Infliximab-EU Remicade (INX) 207/326 (63.5%)
MethotrexateApprovedSmall moleculeDihydrofolate reductase (DHFR), Folate Analog Metabolic InhibitorPartial signal
NCT01185301: DAS28(CRP) < 3.2 at week 26 with adalimumab plus methotrexate 2.5, 5, 10 or 20 mg/week: 42.9%, 44.0%, 56.6% and 60.2% (n=98 to 100 per arm); statistically significant increasing trend with dose (Burmester et al., Ann Rheum Dis 2015).
MethylprednisoloneApprovedSmall moleculeGlucocorticoid receptor agonistnot yet gradedNo reviewed efficacy summary in this indication
PF-05280586ApprovedBiologic (subtype unspecified)CD20Partial signalFeatured results are pharmacokinetic only in this race
Repository Corticotropin (Acthar Gel)ApprovedPeptideMelanocortin receptors (primarily MC2R on the adrenal cortex), Melanocortin 2 receptor (MC2R) (agonist)not yet gradedNo reviewed efficacy summary in this indication
Rituximab (Rituxan)ApprovedMonoclonal antibodyCD20, CD20-directed Cytolytic AntibodyReliable signal
NCT00299130: Percentage of Participants With American College of Rheumatology (ACR) 20 Response at Week 24 (Baseline and Week 24): Rituximab 2 x 0.5 g + MTX 54.5% | Rituximab 2 x 1.0 g + MTX 50.6% vs Placebo + MTX 23.3%
NCT00468546: ACR20 response at week 24: 51.3% (153/298) with rituximab + methotrexate vs 17.9% (36/201) with placebo + methotrexate.
Rituximab-Abbs (Truxima)ApprovedMonoclonal antibodyCD20Reliable signal
NCT02149121: Primary efficacy: DAS28-CRP change from baseline -2.11 with CT-P10 vs -2.10 with reference products; treatment difference -0.01 (90% CI -0.22 to 0.20), with an equivalence margin of ±0.50. Primary PK AUC0-last ratio: 97.07% (CT-P10/Rituxan; 90% CI 88.08% to 106.99%) and 94.18% (CT-P10/MabThera; 90% CI 85.40% to 103.86%).
SarilumabApprovedMonoclonal antibodyIL-6 receptorReliable signal
NCT02332590: DB Period: Change From Baseline in Disease Activity Score for 28 Joints - Erythrocyte Sedimentation Rate (DAS28-ESR) Score at Week 24 (Baseline, Week 24): Sarilumab 200 mg/Sarilumab 200 mg -3.28 units on a scale (Standard Error 0.105) vs Adalimumab 40 mg/Sarilumab 200 mg -2.2 units on a scale (Standard Error 0.106)
NCT01061736: Part A: Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 12 (Baseline to Week 12): Part A: SAR 100 mg qw 62% | Part A: SAR 150 mg qw 72% | Part A: SAR 100 mg q2w 49% | Part A: SAR 150 mg q2w 66.7% | Part A: SAR 200 mg q2w 65.4% vs Part A: Placebo qw 46.2%
SulfasalazineApprovedSmall moleculeAminosalicylatenot yet gradedNo reviewed efficacy summary in this indication
Tocilizumab (Actemra / RoActemra)ApprovedMonoclonal antibodyIL-6 receptorReliable signal
NCT03155347: ACR20 response at Week 24: tocilizumab+methotrexate 52.9% (72/136) vs methotrexate alone 25.0% (17/68), difference 27.9pp (95% CI 14.7-41.2), P<.001; tocilizumab monotherapy 50.0% (68/136) vs methotrexate alone 25.0%, difference 25.0pp (95% CI 11.7-38.3), P<.001
NCT01232569: Percentage of Patients With an American College of Rheumatology 20 (ACR20) Response at Week 24 (Baseline to Week 24): Tocilizumab 162 mg sc 60.9% (95% CI 56.3 to 65.4) vs Placebo sc 31.5% (95% CI 25.4 to 37.7)
Upadacitinib (Rinvoq)ApprovedSmall moleculeJAK, JAK1Reliable signal
NCT03086343: Change from baseline DAS28-CRP at week 12: -2.52 (95% CI -2.66 to -2.37) upadacitinib vs -2.00 (95% CI -2.14 to -1.85) abatacept; upadacitinib met primary non-inferiority and key secondary superiority endpoints.
NCT02706873: Co-primary endpoints: ACR50 at Week 12 -- upadacitinib 15mg 52% (95% CI 47-58), 30mg 56% (95% CI 51-62), MTX 28% (95% CI 23-33), P<0.001 for both doses vs MTX. DAS28-CRP<2.6 at Week 24 -- upadacitinib 15mg 48% (95% CI 43-54), 30mg 50% (95% CI 45-56), MTX 19% (95% CI 14-23), P<0.001 for both doses vs MTX
AcellbiaPhase 3Monoclonal antibodyCD20Reliable signal
NCT02744196: ACR20 response at Week 24 (ALTERRA trial, N=159): Acellbia+MTX 65.7% vs Placebo+MTX 29.4% (p<0.0001); difference 36.3% (95% CI 19.27-53.28%)
Filgotinib (Jyseleca)Phase 3Small moleculeJAK, JAK1Reliable signal
NCT02889796: ACR20 at week 12 (primary endpoint): FIL200 76.6% vs placebo 49.9% (difference 26.7%, 95% CI 20.6-32.8, p<0.001); FIL100 69.8% vs placebo 49.9% (difference 19.9%, 95% CI 13.6-26.2, p<0.001)
NCT02873936: ACR20 response at Week 12: filgotinib 200mg 66.0%, filgotinib 100mg 57.5%, placebo 31.1%; difference vs placebo 34.9% (95% CI 23.5-46.3) and 26.4% (95% CI 15.0-37.9) respectively, both P<.001
HLX01 (Hanlikang)Phase 3Monoclonal antibodyCD20Reliable signalNo reviewed efficacy summary in this indication
IguratimodPhase 3—NF-kBPartial signal
NCT00965757: ACR20 response at week 24: iguratimod plus methotrexate 69.5% vs placebo plus methotrexate 30.7% (P < 0.001), n=164 vs 88 (Ishiguro et al., Mod Rheumatol 2013).
Ivarmacitinib
Phase 3(overall)
Small moleculeJAK
not yet graded(overall)
No reviewed efficacy summary in this indication
Levilimab (Ilsira)Phase 3Monoclonal antibodyIL-6 receptorReliable signal
NCT04227366: ACR20 response at week 12: 68.6% (levilimab + methotrexate) vs 38.5% (placebo + methotrexate).
QLM3003
Phase 3(overall)
Small moleculeJAK
Partial signal(overall)
No reviewed efficacy summary in this indication
TelitaciceptPhase 3Protein / enzyme therapeuticBAFF / APRILnot yet gradedNo reviewed efficacy summary in this indication
ZemprocitinibPhase 3Small moleculeJAK1not yet gradedNo reviewed efficacy summary in this indication
AfimkibartPhase 2Monoclonal antibodyTL1Anot yet gradedNo reviewed efficacy summary in this indication
AZD1163Phase 2Biologic (subtype unspecified)PAD2 and PAD4 (peptidyl arginine deiminase 2/4)not yet gradedNo reviewed efficacy summary in this indication
BlinatumomabPhase 2Multispecific antibodyCD19 x CD3not yet gradedNo reviewed efficacy summary in this indication
CKD-506Phase 2Small moleculeHDAC6 (Histone deacetylase 6)Partial signal
NCT04204603: Primary endpoint, change from baseline in DAS28(CRP) at week 12 (full analysis set, n=121): placebo -1.2, CKD-506 200 mg -1.0, 400 mg -1.3, 600 mg -1.2; pre-specified dose-response trend test p > 0.5 (EudraCT 2018-001377-24 posted results). missed
Denosumab (Prolia)Phase 2Monoclonal antibodyRANKLPartial signal
NCT03239080: Erosion healing at 24 months: 20% (denosumab) vs 6% (placebo), p=0.045.
NCT00095498: Primary endpoint (change from baseline in MRI erosion score at 6 months): denosumab 60 mg +0.13 (P=0.118, not significant) vs denosumab 180 mg +0.06 (P=0.007, significant) vs placebo +1.75. Modified Sharp erosion score: 180 mg significant vs placebo at 6 months (P=0.019); both 60 mg (P=0.012) and 180 mg (P=0.007) significant vs placebo at 12 months.
ImeroprubartPhase 2Monoclonal antibodyFcRnnot yet gradedNo reviewed efficacy summary in this indication
JAB-8263Phase 2Small moleculeBET bromodomain proteins (e.g. BRD4)not yet gradedNo reviewed efficacy summary in this indication
Lepzacitinib
Phase 2(overall)
Small moleculeJAK1/JAK3
not yet graded(overall)
No reviewed efficacy summary in this indication
LutikizumabPhase 2Multispecific antibodyIL-1α/IL-1β (dual)not yet gradedNo reviewed efficacy summary in this indication
MK-8690Phase 2Monoclonal antibodyCD30 ligand (CD30L / CD153)not yet gradedNo reviewed efficacy summary in this indication
NatrunixPhase 2Monoclonal antibodyIL-1 alphaPartial signalNo reviewed efficacy summary in this indication
RavagalimabPhase 2Monoclonal antibodyCD40not yet gradedNo reviewed efficacy summary in this indication
RosnilimabPhase 2Monoclonal antibodyPD-1 (agonist)not yet gradedNo reviewed efficacy summary in this indication
SHR-3045Phase 2UndisclosedPD-1not yet gradedNo reviewed efficacy summary in this indication
ZL-82
Phase 2(overall)
Small moleculeJAK
Weak signal(overall)
No reviewed efficacy summary in this indication
AZD0120Phase 1/2Cell therapyBCMA / CD19not yet gradedNo reviewed efficacy summary in this indication
ABBV-319Phase 1Antibody–drug conjugateCD19not yet gradedNo reviewed efficacy summary in this indication
ABBV-519Phase 1—CD19not yet gradedNo reviewed efficacy summary in this indication
AZD5492Phase 1Multispecific antibodyCD20 x CD3not yet gradedNo reviewed efficacy summary in this indication
AZD6912Phase 1RNA / oligonucleotideComplement Factor B (CFB) mRNAWeak signalNo reviewed efficacy summary in this indication
BMS-986454Phase 1—PAD4 (peptidylarginine deiminase 4)not yet gradedNo reviewed efficacy summary in this indication
CLN-978Phase 1Multispecific antibodyCD19 x CD3not yet gradedNo reviewed efficacy summary in this indication
CND261Phase 1Biologic (subtype unspecified)CD20 x CD3not yet gradedNo reviewed efficacy summary in this indication
S-4321Phase 1Multispecific antibodyPD-1 / FcγRIIb (dual)not yet gradedNo reviewed efficacy summary in this indication

Large race: only the 68 furthest-along competitors are listed; 19 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(22 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Xeljanz (tofacitinib) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (3)
December 2026 (3)
Phase 1Healthy VolunteersRecruiting
Est. primary completion 2026-12 · NCT07843693 · CT.gov ↗
What to watch
Early phase / not applicableChronic Plaque PsoriasisNot yet recruiting
Est. primary completion 2026-12-01 · NCT07581418 · CT.gov ↗
What to watch
Phase 1Vitiligo, GeneralizedNot yet recruiting
Est. primary completion 2026-12-31 · NCT07055529 · CT.gov ↗
What to watch
2027 (10)
January 2027 (2)
Phase 4Oral Lichen PlanusRecruiting
Est. primary completion 2027-01-01 · NCT07131813 · CT.gov ↗
What to watch
Phase 4Rheumatoid ArthritisNot yet recruiting
Est. primary completion 2027-01-31 · NCT06945666 · CT.gov ↗
What to watch
March 2027 (2)
Phase 4Rheumatoid ArthritisNot yet recruiting
Est. primary completion 2027-03-05 · NCT07636057 · CT.gov ↗
What to watch
Phase 3Ulcerative ColitisActive not recruiting
Est. primary completion 2027-03-17 · NCT04624230 · CT.gov ↗
What to watch
April 2027 (1)
Phase 2Nail PsoriasisActive not recruiting
Est. primary completion 2027-04 · NCT07313072 · CT.gov ↗
What to watch
July 2027 (2)
Early phase / not applicableErythematotelangiectatic RosaceaRecruiting
Est. primary completion 2027-07-01 · NCT07343635 · CT.gov ↗
What to watch
Phase 4Ulcerative ColitisActive not recruiting
Est. primary completion 2027-07-09 · NCT06095128 · CT.gov ↗
What to watch
August 2027 (1)
Phase 2Patients With Locally Advanced or Metastatic NSCLC Who Have Failed First-line ImmunotherapyRecruiting
Est. primary completion 2027-08-30 · NCT07925866 · CT.gov ↗
What to watch
October 2027 (1)
Phase 4Blau SyndromeEnrolling by invitation
Est. primary completion 2027-10-01 · NCT06660329 · CT.gov ↗
What to watch
December 2027 (1)
Phase 2Thyroid Eye Disease, TED, Graves Ophthalmopathy, Graves OrbitopathyRecruiting
Est. primary completion 2027-12-30 · NCT07547930 · CT.gov ↗
What to watch
2028 (3)
January 2028 (1)
Phase 2Rheumatic DiseaseRecruiting
Est. primary completion 2028-01 · NCT07138898 · CT.gov ↗
What to watch
March 2028 (1)
Phase 3Rheumatoid ArthritisRecruiting
Est. primary completion 2028-03 · NCT03414502 · CT.gov ↗
What to watch
October 2028 (1)
Phase 3Granulomatosis With Polyangiitis, Anti-neutrophil Cytoplasmic Antibody-associated VasculitisRecruiting
Est. primary completion 2028-10 · NCT04871191 · CT.gov ↗
What to watch
2029 (3)
April 2029 (1)
Phase 4Rheumatoid ArthritisRecruiting
Est. primary completion 2029-04-01 · NCT06687551 · CT.gov ↗
What to watch
May 2029 (1)
Phase 3Polyarticular Course Juvenile Idiopathic Arthritis (JIA)Recruiting
Est. primary completion 2029-05-30 · NCT06654882 · CT.gov ↗
What to watch
December 2029 (1)
Phase 2LALNot yet recruiting
Est. primary completion 2029-12-01 · NCT07522801 · CT.gov ↗
What to watch
2030 (3)
June 2030 (1)
Phase 4Psoriasis, Atopic DermatitisNot yet recruiting
Est. primary completion 2030-06-01 · NCT07352566 · CT.gov ↗
What to watch
August 2030 (1)
Phase 2Down SyndromeRecruiting
Est. primary completion 2030-08 · NCT07598643 · CT.gov ↗
What to watch
December 2030 (1)
Phase 2Sjogren's SyndromeRecruiting
Est. primary completion 2030-12-15 · NCT07281456 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Coming up

November 2026ApprovalFDA updates Boxed Warning on Xeljanz (NDA203214)
US, FDA · FDA · Source ↗